Key result
Infusion of the endothelin A antagonist BQ-123 in healthy men increased fractional excretion of sodium (20%) and decreased diastolic blood pressure (-6.3%) at a medium dose.
Why the study?
Does BQ-123 alter renal hemodynamics, tubular function, vasoactive hormones, and blood pressure in healthy men?
Population
11 healthy men
Comparison
BQ-123 infused intravenously at 0.1, 0.2, and… vs Placebo
Design
RCT, randomized, double-blind
Follow-up
1 hour (measured before, during, and after infusion)
Authors
Loading...
Endothelin A antagonism increases natriuresis and lowers diastolic BP in healthy men; extends mechanistic data to humans and supports trials in hypertension.
RCT (n=11)
Double-blind
Randomized
Does BQ-123 alter renal hemodynamics, tubular function, vasoactive hormones, and blood pressure in healthy men?
Endothelin A antagonism with BQ-123 increases renal sodium excretion and decreases diastolic blood pressure in healthy men, despite stimulating the renin-angiotensin system.
Pedersen et al. (2005) conducted an RCT in Healthy (n=11). BQ-123 vs. Placebo was evaluated on Renal hemodynamics, tubular function, vasoactive hormones, and blood pressure. Infusion of the endothelin A antagonist BQ-123 in healthy men increased fractional excretion of sodium (20%) and decreased diastolic blood pressure (-6.3%) at a medium dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: